MiRagen Therapeutics, Inc., is a biopharmaceutical company founded to harness the power of microRNA (miRNA) biology and develop innovative microRNA-based therapeutics for cardiovascular and muscle disease. In October 2011, miRagen and Les Laboratoires Servier, a leading European pharmaceutical company, entered into a strategic alliance for the research and development of microRNA-based therapeutics for the treatment of patients afflicted with cardiovascular disease.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/24/12 | $20,000,000 | Series B |
Amgen Business Development Atlas Venture Broadview Ventures | undisclosed |
| 11/10/15 | $41,000,000 | Series C |
Amgen Business Development Atlas Venture Boulder Ventures Brace Pharma JAFCO MP Healthcare Venture Management Remeditex Ventures | undisclosed |
